Professor Ludmil Alexandrov from the University of California, San Diego, is set to lead an international team awarded $25 million to investigate cancer mutations. The funding comes from Cancer Grand Challenges, a partnership between Cancer Research UK and the U.S. National Cancer Institute, which has allocated over $400 million to multidisciplinary research aimed at addressing significant challenges in cancer.
New Leadership and Ambitious Goals
Dr. Alexandrov holds a doctorate in computational biology from Cambridge University, earned in 2014. His experience with Cancer Grand Challenges is notable; he was part of the “Team Mutographs,” which previously received a $25 million grant in 2017. That initiative documented how various cancer-causing events create unusual patterns of mutation, resulting in 38 research publications and the development of eight tools for analyzing mutational signals in cells.
Now, under Alexandrov’s leadership, the new team, dubbed “CAUSE,” aims to uncover the origins of mutations. This research will focus on identifying “adducts,” which are chemicals from environmental sources or biological processes that can attach to DNA, leading to misread genetic instructions and potentially causing mutations during cell replication.
Collaborative Research Efforts
The CAUSE team includes prominent scientists such as Silvia Balbo from the University of Minnesota, Emily Balskus of Harvard University, Juan Garaycoechea of the Hubrecht Institute in the Netherlands, and Inigo Martincorena at the Wellcome Sanger Institute in the United Kingdom, among others. This collaboration reflects a global effort to tackle the complexities of cancer mutations through diverse expertise.
A notable contribution from the previous Team Mutographs project was a paper published in the journal Nature on April 23. This study examined mutational signatures in early-onset colorectal cancer, which has been rising in prevalence across various countries. The analysis, which included data from 981 genomes collected from 11 countries, revealed that exposure to a toxin produced by certain bacteria, including E. coli, during childhood significantly increases the risk of developing colorectal cancer before the age of 50.
While in Europe to accept the award, Alexandrov was unable to provide additional comments. Nevertheless, in a university statement, he expressed optimism about the research’s potential impact: “The ability to decode the origins of mutational signatures has the potential to revolutionize our understanding of cancer. We believe that our research will pave the way for new discoveries and new treatments, ultimately improving outcomes for patients worldwide.”
As this ambitious project unfolds, the collaboration of these leading scientists may yield groundbreaking insights into the mechanisms that underlie cancer mutations, potentially transforming approaches to prevention and treatment in the future.
